NTLA · Categories · Form 4
NTLA - SEC Form 4 insider transactions
Intellia Therapeutics Inc. (NTLA) sec form 4 insider transactions - real-time wire coverage filtered to Form 4 only.
Recent Form 4 for NTLA
- EVP, General Counsel Basta James was granted 46,080 shares and sold $16,688 worth of shares (1,211 units at $13.78), increasing direct ownership by 40% to 156,794 units (SEC Form 4)4 - Intellia Therapeutics, Inc. (0001652130) (Issuer)
- President and CEO Leonard John M was granted 156,400 shares, increasing direct ownership by 15% to 1,169,739 units (SEC Form 4)4 - Intellia Therapeutics, Inc. (0001652130) (Issuer)
- VP, Chief Accounting Officer Dube Michael P was granted 17,250 shares, increasing direct ownership by 33% to 69,527 units (SEC Form 4)4 - Intellia Therapeutics, Inc. (0001652130) (Issuer)
- EVP, Chief Financial Officer Dulac Edward J Iii was granted 61,280 shares, increasing direct ownership by 61% to 160,963 units (SEC Form 4)4 - Intellia Therapeutics, Inc. (0001652130) (Issuer)
- EVP, Chief Scientific Officer Schultes Birgit C was granted 39,200 shares, increasing direct ownership by 40% to 137,733 units (SEC Form 4)4 - Intellia Therapeutics, Inc. (0001652130) (Issuer)
- EVP, Chief Technical Officer Clark Eliana was granted 7,353 shares and sold $8,364 worth of shares (607 units at $13.78), increasing direct ownership by 8% to 93,864 units (SEC Form 4)4 - Intellia Therapeutics, Inc. (0001652130) (Issuer)
- EVP, Chief Medical Officer Lebwohl David was granted 9,943 shares, increasing direct ownership by 8% to 131,192 units (SEC Form 4)4 - Intellia Therapeutics, Inc. (0001652130) (Issuer)
- President and CEO Leonard John M sold $314,485 worth of shares (34,146 units at $9.21), decreasing direct ownership by 3% to 1,013,339 units (SEC Form 4)4 - Intellia Therapeutics, Inc. (0001652130) (Issuer)
- EVP, Chief Scientific Officer Schultes Birgit C sold $78,359 worth of shares (8,508 units at $9.21), decreasing direct ownership by 8% to 98,533 units (SEC Form 4)4 - Intellia Therapeutics, Inc. (0001652130) (Issuer)
- EVP, Chief Medical Officer Lebwohl David sold $109,627 worth of shares (11,903 units at $9.21), decreasing direct ownership by 9% to 121,249 units (SEC Form 4)4 - Intellia Therapeutics, Inc. (0001652130) (Issuer)
- EVP, General Counsel Basta James sold $95,756 worth of shares (10,397 units at $9.21), decreasing direct ownership by 9% to 101,528 units (SEC Form 4)4 - Intellia Therapeutics, Inc. (0001652130) (Issuer)
- EVP, Chief Technical Officer Clark Eliana sold $87,633 worth of shares (9,515 units at $9.21), decreasing direct ownership by 10% to 87,118 units (SEC Form 4)4 - Intellia Therapeutics, Inc. (0001652130) (Issuer)
- EVP, Chief Financial Officer Dulac Edward J Iii sold $58,751 worth of shares (6,379 units at $9.21), decreasing direct ownership by 6% to 99,683 units (SEC Form 4)4 - Intellia Therapeutics, Inc. (0001652130) (Issuer)
- VP, Chief Accounting Officer Dube Michael P sold $27,529 worth of shares (2,989 units at $9.21), decreasing direct ownership by 5% to 52,277 units (SEC Form 4)4 - Intellia Therapeutics, Inc. (0001652130) (Issuer)
- President and CEO Leonard John M exercised 58,516 shares at a strike of $6.83 and sold $836,384 worth of shares (88,146 units at $9.49), decreasing direct ownership by 3% to 1,047,485 units (SEC Form 4)4 - Intellia Therapeutics, Inc. (0001652130) (Issuer)
- EVP, Chief Scientific Officer Schultes Birgit C sold $539 worth of shares (31 units at $17.38), decreasing direct ownership by 0.03% to 105,184 units (SEC Form 4)4 - Intellia Therapeutics, Inc. (0001652130) (Issuer)
- VP, Chief Accounting Officer Dube Michael P sold $32,518 worth of shares (1,871 units at $17.38), decreasing direct ownership by 3% to 55,266 units (SEC Form 4)4 - Intellia Therapeutics, Inc. (0001652130) (Issuer)
- EVP, Chief Financial Officer Dulac Edward J Iii sold $104,617 worth of shares (7,462 units at $14.02), decreasing direct ownership by 7% to 106,062 units (SEC Form 4)4 - Intellia Therapeutics, Inc. (0001652130) (Issuer)
- EVP, Chief Technical Officer Clark Eliana sold $10,036 worth of shares (1,022 units at $9.82), decreasing direct ownership by 1% to 95,369 units (SEC Form 4)4 - Intellia Therapeutics, Inc. (0001652130) (Issuer)
- VP, Chief Accounting Officer Dube Michael P sold $24,905 worth of shares (2,503 units at $9.95), decreasing direct ownership by 4% to 57,137 units (SEC Form 4)4 - Intellia Therapeutics, Inc. (0001652130) (Issuer)
- Director Goodman Jesse sold $29,068 worth of shares (3,094 units at $9.40), decreasing direct ownership by 11% to 24,359 units (SEC Form 4)4 - Intellia Therapeutics, Inc. (0001652130) (Issuer)
- Director Keresty Georgia was granted 8,000 shares, increasing direct ownership by 33% to 31,883 units (SEC Form 4)4 - Intellia Therapeutics, Inc. (0001652130) (Issuer)
- Director Verwiel Frank was granted 8,000 shares, increasing direct ownership by 45% to 25,948 units (SEC Form 4)4 - Intellia Therapeutics, Inc. (0001652130) (Issuer)
- Director Goodman Jesse was granted 8,000 shares, increasing direct ownership by 41% to 27,453 units (SEC Form 4)4 - Intellia Therapeutics, Inc. (0001652130) (Issuer)
- Director Goff Brian was granted 8,000 shares, increasing direct ownership by 52% to 23,409 units (SEC Form 4)4 - Intellia Therapeutics, Inc. (0001652130) (Issuer)
- Director Bhanji Muna was granted 8,000 shares, increasing direct ownership by 42% to 27,203 units (SEC Form 4)4 - Intellia Therapeutics, Inc. (0001652130) (Issuer)
- Director Chase William J was granted 8,000 shares, increasing direct ownership by 30% to 34,693 units (SEC Form 4)4 - Intellia Therapeutics, Inc. (0001652130) (Issuer)
- Director Cohen Fred E was granted 8,000 shares, increasing direct ownership by 16% to 57,453 units (SEC Form 4)4 - Intellia Therapeutics, Inc. (0001652130) (Issuer)
- Director Bhanji Muna sold $2,252 worth of shares (265 units at $8.50), decreasing direct ownership by 1% to 19,203 units (SEC Form 4)4 - Intellia Therapeutics, Inc. (0001652130) (Issuer)
- EVP, Chief Technical Officer Clark Eliana was granted 32,000 shares and sold $6,104 worth of shares (679 units at $8.99), increasing direct ownership by 49% to 95,369 units (SEC Form 4)4 - Intellia Therapeutics, Inc. (0001652130) (Issuer)
- President and CEO Leonard John M was granted 136,000 shares, increasing direct ownership by 14% to 1,077,115 units (SEC Form 4)4 - Intellia Therapeutics, Inc. (0001652130) (Issuer)
- EVP, Chief Financial Officer Dulac Edward J Iii was granted 47,200 shares, increasing direct ownership by 71% to 113,524 units (SEC Form 4)4 - Intellia Therapeutics, Inc. (0001652130) (Issuer)
- VP, Chief Accounting Officer Dube Michael P was granted 14,000 shares, increasing direct ownership by 31% to 59,640 units (SEC Form 4)4 - Intellia Therapeutics, Inc. (0001652130) (Issuer)
- EVP, Chief Medical Officer Lebwohl David was granted 43,200 shares, increasing direct ownership by 49% to 130,866 units (SEC Form 4)4 - Intellia Therapeutics, Inc. (0001652130) (Issuer)
- EVP, Chief Scientific Officer Schultes Birgit C was granted 37,600 shares, increasing direct ownership by 56% to 105,215 units (SEC Form 4)4 - Intellia Therapeutics, Inc. (0001652130) (Issuer)
- EVP, General Counsel Basta James was granted 40,000 shares and sold $23,122 worth of shares (2,572 units at $8.99), increasing direct ownership by 50% to 111,925 units (SEC Form 4)4 - Intellia Therapeutics, Inc. (0001652130) (Issuer)
- Director Bhanji Muna sold $2,642 worth of shares (265 units at $9.97), decreasing direct ownership by 1% to 19,468 units (SEC Form 4)4 - Intellia Therapeutics, Inc. (0001652130) (Issuer)
- VP, Chief Accounting Officer Dube Michael P sold $16,711 worth of shares (1,372 units at $12.18), decreasing direct ownership by 3% to 45,640 units (SEC Form 4)4 - Intellia Therapeutics, Inc. (0001652130) (Issuer)
- EVP, General Counsel Basta James sold $86,161 worth of shares (7,074 units at $12.18), decreasing direct ownership by 9% to 74,497 units (SEC Form 4)4 - Intellia Therapeutics, Inc. (0001652130) (Issuer)
- EVP, Chief Business Officer Hicks Derek sold $79,194 worth of shares (6,502 units at $12.18), decreasing direct ownership by 10% to 59,878 units (SEC Form 4)4 - Intellia Therapeutics, Inc. (0001652130) (Issuer)
- EVP, Chief Medical Officer Lebwohl David sold $116,404 worth of shares (9,557 units at $12.18), decreasing direct ownership by 10% to 87,666 units (SEC Form 4)4 - Intellia Therapeutics, Inc. (0001652130) (Issuer)
- President and CEO Leonard John M sold $326,509 worth of shares (26,807 units at $12.18), decreasing direct ownership by 3% to 941,115 units (SEC Form 4)4 - Intellia Therapeutics, Inc. (0001652130) (Issuer)
- EVP, Chief Scientific Officer Sepp-Lorenzino Laura sold $109,206 worth of shares (8,966 units at $12.18), decreasing direct ownership by 10% to 77,388 units (SEC Form 4)4 - Intellia Therapeutics, Inc. (0001652130) (Issuer)
- EVP, Chief Technical Officer Clark Eliana sold $97,089 worth of shares (7,978 units at $12.17), decreasing direct ownership by 11% to 64,048 units (SEC Form 4)4 - Intellia Therapeutics, Inc. (0001652130) (Issuer)
- EVP, Chief Medical Officer Lebwohl David converted options into 3,189 shares, increasing direct ownership by 3% to 97,223 units (SEC Form 4)4 - Intellia Therapeutics, Inc. (0001652130) (Issuer)
- President and CEO Leonard John M converted options into 7,850 shares, increasing direct ownership by 0.82% to 967,922 units (SEC Form 4)4 - Intellia Therapeutics, Inc. (0001652130) (Issuer)
- EVP, Chief Scientific Officer Sepp-Lorenzino Laura converted options into 3,500 shares, increasing direct ownership by 4% to 86,354 units (SEC Form 4)4 - Intellia Therapeutics, Inc. (0001652130) (Issuer)
- VP, Chief Accounting Officer Dube Michael P sold $38,248 worth of shares (2,012 units at $19.01), decreasing direct ownership by 4% to 47,012 units (SEC Form 4)4 - Intellia Therapeutics, Inc. (0001652130) (Issuer)
- EVP, Chief Financial Officer Dulac Edward J Iii was granted 66,324 shares (SEC Form 4)4 - Intellia Therapeutics, Inc. (0001652130) (Issuer)
- VP, PAO and Interim PFO Dube Michael P was granted 17,801 shares, increasing direct ownership by 57% to 49,024 units (SEC Form 4)4 - Intellia Therapeutics, Inc. (0001652130) (Issuer)
- EVP, Chief Technical Officer Clark Eliana sold $9,287 worth of shares (405 units at $22.93), decreasing direct ownership by 0.56% to 71,470 units (SEC Form 4)4 - Intellia Therapeutics, Inc. (0001652130) (Issuer)
- Director Verwiel Frank sold $37,625 worth of shares (1,505 units at $25.00), decreasing direct ownership by 8% to 17,948 units (SEC Form 4)4 - Intellia Therapeutics, Inc. (0001652130) (Issuer)
- Director Goff Brian was granted 15,409 shares (SEC Form 4)4 - Intellia Therapeutics, Inc. (0001652130) (Issuer)
- Director Verwiel Frank was granted 7,737 shares, increasing direct ownership by 66% to 19,453 units (SEC Form 4)4 - Intellia Therapeutics, Inc. (0001652130) (Issuer)
- Director Keresty Georgia was granted 7,737 shares, increasing direct ownership by 48% to 23,883 units (SEC Form 4)4 - Intellia Therapeutics, Inc. (0001652130) (Issuer)
- Director Goodman Jesse was granted 7,737 shares, increasing direct ownership by 66% to 19,453 units (SEC Form 4)4 - Intellia Therapeutics, Inc. (0001652130) (Issuer)
- Director Cohen Fred E was granted 7,737 shares, increasing direct ownership by 19% to 49,453 units (SEC Form 4)4 - Intellia Therapeutics, Inc. (0001652130) (Issuer)
- Director Bhanji Muna was granted 7,737 shares, increasing direct ownership by 64% to 19,733 units (SEC Form 4)4 - Intellia Therapeutics, Inc. (0001652130) (Issuer)
- Director Chase William J was granted 7,737 shares, increasing direct ownership by 41% to 26,693 units (SEC Form 4)4 - Intellia Therapeutics, Inc. (0001652130) (Issuer)
- Goddard Glenn was granted 28,628 shares, increasing direct ownership by 71% to 69,213 units (SEC Form 4)4 - Intellia Therapeutics, Inc. (0001652130) (Issuer)